At a glance
ClinicalIndex Comparison RecordN/ACompleted· 292 enrolled
Drug / intervention
Brentuximab vedotin (recombinant)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Brentuximab Vedotin (ADCETRIS) IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
In Brief
An observational study evaluating Brentuximab vedotin (recombinant) for Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma. Completed, enrolled 292 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety of brentuximab vedotin (recombinant) for intravenous (IV) infusion (ADCETRIS IV Infusion 50 mg) in patients with relapsed/refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymphoma in the routine clinical setting, as well as to collect efficacy information for reference.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
First PostedMay 2014
Primary CompletionJun 2017
TodayJul 2026
First PostedMay 15, 2014
Enrollment StartApr 17, 2014
Primary CompletionJun 30, 2017
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 12.1 years ago
Interventions
Brentuximab vedotin (recombinant)drug
Brentuximab vedotin (recombinant) for IV infusion